New drug cocktail aims to tackle resistant lung cancer
NCT ID NCT07193160
First seen Nov 01, 2025 · Last updated Jun 20, 2026 · Updated 29 times
Summary
This phase II trial tests a combination of two drugs—sacituzumab tirumotecan and furmonertinib—in 45 people with advanced EGFR-mutant non-small cell lung cancer whose first targeted therapy stopped working. The study measures how many patients respond to treatment and how long the benefit lasts. It is a single-arm, open-label trial, meaning everyone gets the same treatment and there is no placebo group.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NSCLC (NON-SMALL CELL LUNG CANCER) are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
sacituzumab tirumotecan (a drug that targets cancer cells) and furmonertinib (a targeted therapy pill)
What this could lead to
If this combination works, it could offer a new second-line treatment option for people with a specific type of advanced lung cancer whose first treatment stopped working.
What could go wrong
This is a small, early-phase (Phase II) trial with only 45 people and no comparison group, so results may not apply broadly. The drug combination may cause side effects or not improve outcomes significantly.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.